
ATAI Stock Forecast & Price Target
ATAI Analyst Ratings
Bulls say
Atai Beckley NV's clinical candidate BPL-003 has shown promising results, exhibiting significantly improved MADRS scores and a doubling of remission rates after the second dose, indicating a potential for enhanced clinical response. With an estimated 20% market share by 2035 due to its clinical differentiation, the company appears well-positioned for growth in the treatment-resistant depression sector. Furthermore, the strong year-to-date stock performance, coupled with anticipated regulatory alignment for Phase 3 trials and upcoming efficacy data, suggests continued optimism regarding its clinical pipeline and market potential.
Bears say
Atai Beckley NV's clinical trials indicate a concerning decline in efficacy of its treatments, with significant deterioration observed in both VLS-01 and BPL-003 from earlier assessment points. The company's Phase 3 results showed a placebo-adjusted change in the MADRS score that lagged behind competitors, such as Spravato, highlighting a potential competitive disadvantage in efficacy metrics. Furthermore, limited safety data from preliminary studies raises questions about the risk profile of the company's dual-dose induction therapy, compounding the uncertainty around its upcoming projects and overall market viability.
This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.
ATAI Analyst Forecast & Price Prediction
Start investing in ATAI
Order type
Buy in
Order amount
Est. shares
0 shares